Sensitive and Robust Method for Estimation of Mometasone at Sub-pg/mL in Human Plasma Using Shimadzu LCMS-8060NX

User Benefits

- Simple, Selective and most sensitive method with LLOQ of 0.5 pg/mL - Linear dynamic range suitable for PK studies and range between 0.5 pg/mL to 20 pg/mL - Single step sample extraction method increased sample productivity

Introduction

Mometasone furoate is a long-acting beta2-agonist used in the management of asthma and/or chronic obstructive pulmonary disease (COPD). Inhaled Mometasone works like other beta2- agonists, causing bronchodilatation by relaxing the smooth muscle in the airway so as to treat the exacerbation of asthma. Mometasone furoate is a corticosteroid used as an anti- inflammatory and chemical name is (11β, 16α)-9, 21-dichloro- 11-hydroxy-16- methyl-3, 20-dioxopregna-1, 4-dien-17-yl 2- furoate. Mometasone have very less bioavailability (less than 1 %) and very low circulating plasma concentrations (50 pg/mL) following a 100–400 µg inhaled dose, accurate quantification of mometasone from plasma can be challenging. In this work, a robust, sensitive, and selective method was developed for the accurate quantification of mometasone furoate. Such method should address many problems such as low Bioavailability, carry-over and low extraction recovery. We have therefore developed a method with high chromatographic resolution and ample sensitivity giving lowest limit of quantification (LLOQ) of 0.50 pg/mL for Mometasone in human plasma using LCMS-8060NX. Method was developed keeping some key criteria in focus- namely simpler extraction procedure, highly optimized chromatography and enhanced sensitivity. These factors enable selective and high-throughput analysis of Mometasone for the pharmacokinetic investigation.

January 22, 2024 GMT